CA2925057A1 - Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer - Google Patents
Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer Download PDFInfo
- Publication number
- CA2925057A1 CA2925057A1 CA2925057A CA2925057A CA2925057A1 CA 2925057 A1 CA2925057 A1 CA 2925057A1 CA 2925057 A CA2925057 A CA 2925057A CA 2925057 A CA2925057 A CA 2925057A CA 2925057 A1 CA2925057 A1 CA 2925057A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- beta
- inhibitor
- her2
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885302P | 2013-10-01 | 2013-10-01 | |
| US61/885,302 | 2013-10-01 | ||
| PCT/EP2014/071028 WO2015049280A1 (en) | 2013-10-01 | 2014-10-01 | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2925057A1 true CA2925057A1 (en) | 2015-04-09 |
Family
ID=51655742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2925057A Abandoned CA2925057A1 (en) | 2013-10-01 | 2014-10-01 | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160319032A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3052523B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6527508B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106232625B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014331118B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2925057A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015049280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| JP7107839B2 (ja) * | 2015-12-11 | 2022-07-27 | ルプレヒト－カールス－ウニベルジテート ハイデルベルク | Ｐｋｍ２モジュレーター及びｈｍｇｂ１の組合せ製剤 |
| JP7030066B2 (ja) | 2016-05-26 | 2022-03-04 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｅｇｆｒ阻害剤化合物 |
| TWI802193B (zh) * | 2016-06-14 | 2023-05-11 | 美商默沙東有限責任公司 | 抗凝血因子ｘｉ抗體 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN106950371B (zh) * | 2017-02-17 | 2019-03-08 | 张灏 | Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途 |
| JP2020512978A (ja) * | 2017-03-31 | 2020-04-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US20220211783A1 (en) * | 2019-02-22 | 2022-07-07 | Candel Therapeutics, Inc. | Gmci and ddri combination therapy for treating cancer |
| IL293195A (en) | 2019-12-05 | 2022-07-01 | Seagen Inc | Anti-avb6 antibodies and antibody-drug conjugates |
| CN114195893A (zh) * | 2020-09-17 | 2022-03-18 | 百奥泰生物制药股份有限公司 | 抗整联蛋白抗体或抗原结合片段及其应用 |
| CN117603348B (zh) * | 2023-11-24 | 2024-08-09 | 优睿赛思(武汉)生物科技有限公司 | 抗新型冠状病毒s蛋白的全人源化抗体及其应用 |
| EP4595981A1 (en) * | 2024-02-01 | 2025-08-06 | Jack Elands | Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody |
| WO2025163120A1 (en) | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0308585B8 (pt) * | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| CA2658612C (en) * | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
| MX360141B (es) * | 2012-02-17 | 2018-10-24 | Seattle Genetics Inc | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. |
-
2014
- 2014-10-01 WO PCT/EP2014/071028 patent/WO2015049280A1/en not_active Ceased
- 2014-10-01 EP EP14777632.2A patent/EP3052523B1/en not_active Not-in-force
- 2014-10-01 CA CA2925057A patent/CA2925057A1/en not_active Abandoned
- 2014-10-01 CN CN201480065738.4A patent/CN106232625B/zh active Active
- 2014-10-01 JP JP2016519326A patent/JP6527508B2/ja active Active
- 2014-10-01 AU AU2014331118A patent/AU2014331118B2/en active Active
- 2014-10-01 US US15/026,350 patent/US20160319032A1/en not_active Abandoned
-
2018
- 2018-11-06 US US16/181,907 patent/US20190389967A1/en not_active Abandoned
-
2019
- 2019-03-20 JP JP2019052035A patent/JP2019142876A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015049280A1 (en) | 2015-04-09 |
| HK1232235A1 (zh) | 2018-01-05 |
| CN106232625B (zh) | 2020-04-24 |
| US20190389967A1 (en) | 2019-12-26 |
| EP3052523A1 (en) | 2016-08-10 |
| CN106232625A (zh) | 2016-12-14 |
| EP3052523B1 (en) | 2021-03-10 |
| AU2014331118B2 (en) | 2019-07-25 |
| AU2014331118A1 (en) | 2016-05-19 |
| JP2016539083A (ja) | 2016-12-15 |
| JP2019142876A (ja) | 2019-08-29 |
| JP6527508B2 (ja) | 2019-06-05 |
| US20160319032A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014331118B2 (en) | Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer | |
| CA2658612C (en) | Antibodies directed to .alpha.v.beta.6 and uses thereof | |
| US8119130B2 (en) | Targeted binding agents directed to KDR and uses thereof—035 | |
| US8026344B2 (en) | Targeted binding agents directed to uPAR and uses thereof | |
| US20120107324A1 (en) | TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF | |
| JP2012502649A (ja) | Ｃｄ１０５を対象とする標的結合剤およびその使用 | |
| EP2379595A2 (en) | Targeted binding agents directed to 5 1 and uses thereof | |
| WO2010072741A9 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR | |
| HK1232235B (zh) | 治疗和诊断过表达α-V-β-6 的癌症的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190814 |
|
| FZDE | Discontinued |
Effective date: 20220509 |
|
| FZDE | Discontinued |
Effective date: 20220509 |